Pharvaris/$PHVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pharvaris

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Ticker

$PHVS
Sector
Health
Primary listing
NASDAQ

Employees

114

Headquarters

Zug, Switzerland
Website
pharvaris.com

Pharvaris Metrics

BasicAdvanced
$1.7B
-
-$3.63
-2.81
-

What the Analysts think about Pharvaris

Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.

Bulls say / Bears say

Pharvaris held €281 million in cash and cash equivalents as of December 31, 2024, underpinning its ability to fund late-stage clinical programs through key data readouts (GlobeNewswire)
The RAPIDe-3 pivotal Phase 3 study reached target enrollment of approximately 120 participants by Q3 2024, strengthening confidence in the on-demand treatment development timeline (GlobeNewswire)
Deucrictibant received orphan medicinal product designation from the European Commission in March 2025, offering regulatory incentives and market exclusivity potential in the EU (GlobeNewswire)
R&D expenses rose to €30.9 million in Q1 2025 from €18.5 million a year earlier, while G&A expenses increased to €11.3 million from €9.8 million, contributing to a €46.3 million net loss and accelerating cash burn (GlobeNewswire)
Topline data for the pivotal RAPIDe-3 on-demand study and the CHAPTER-3 prophylaxis trial are not expected until Q1 2026 and H2 2026, respectively, delaying potential approval and commercialization milestones (GlobeNewswire)
Pharvaris’ pipeline is entirely concentrated on a single asset, deucrictibant, creating significant binary risk should any pivotal trial fail (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Pharvaris Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Pharvaris Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PHVS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs